Compare Boston Scientific Corporation (BSX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Under Armour Inc Class A — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Under Armour Inc Class A trades at $6.61 (market cap $2.79B). The key difference: Boston Scientific Corporation is far larger — about 23.8× Under Armour Inc Class A's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | UAA | |
|---|---|---|
Market Cap | $66.37B | $2.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $8.14 |
52-Week Low | $42.63 | $4.17 |
Enterprise Value | $75.94B | $4.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Under Armour (UAA) trades at $6.75, down 0.59% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Fundamentally, the company reported a net loss of $201.27 million in 2025 despite beating EPS expectations in two recent quarters, with revenue declining to $5.16 billion. Analyst sentiment is cautious with a consensus price target of $5.96, below the current price, and news highlights ongoing challenges in North America offset by international growth.
The outlook remains challenging with weak guidance for FY2027 and margin pressure, though international expansion and a recent Dodge collaboration offer potential catalysts. Key risks include persistent North American weakness, rising costs, and high debt levels. Investors face a stock with negative profitability metrics trading above analyst targets, suggesting limited near-term upside absent a significant operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
